

# Support During Conventional Treatments

## Professor Kerry Bone's Reading Assignment



### Module 3.2 – Overview and Potential for Harmful Interactions

- 1. Evidence-Based Management of Herb-Drug Interaction in Cancer Chemotherapy**  
Cheng, C. W., Fan, W., Ko, S. G., Song, L., & Bian, Z. X. (2010). Evidence-based management of herb-drug interaction in cancer chemotherapy. *Explore: The Journal of Science and Healing*, 6(5), 324-329.
- 2. National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients with**  
Lee, R. T., Barbo, A., Lopez, G., Melhem-Bertrandt, A., Lin, H., Olopade, O. I., & Curlin, F. A. (2014). National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. *Journal of Clinical Oncology*, 32(36), 4095.

### Advanced Reading

- 1. Drug Interactions with Phytotherapeutics in Oncology**  
Haefeli, W. E., & Carls, A. (2014). Drug interactions with phytotherapeutics in oncology. *Expert opinion on drug metabolism & toxicology*, 10(3), 359-377.
- 2. Relevance of In Vitro and Clinical Data for Predicting CYP3A4-Mediated Herb–Drug Interactions in Cancer Patients**  
Goey, A. K., Mooiman, K. D., Beijnen, J. H., Schellens, J. H., & Meijerman, I. (2013). Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb–drug interactions in cancer patients. *Cancer treatment reviews*, 39(7), 773-783.
- 3. Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: a Systematic Review and Quantitative Analysis**  
Kovic, B., Jin, X., Kennedy, S. A., Hylands, M., Pędziwiatr, M., Kuriyama, A., ... & Hong, B. Y. (2018). Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis. *JAMA internal medicine*, 178(12), 1586-1596.